Sub Banner Image

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death

Market Impact

Vandana Singh

·

September 2, 2025

·

Benzinga

Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths.

read more

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.